Alan J. Koletsky
Impact in
-
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
Papers in
-
- Prostate Cancer Treatment and Research 6
- Lung Cancer Treatments and Mutations 3
- Lung Cancer Diagnosis and Treatment 2
- Renal cell carcinoma treatment 2
- Oncology 6
- HER2/EGFR in Cancer Research 3
- Drug Transport and Resistance Mechanisms 2
- Co-authors
- Robert E. Handschumacher (3 shared papers)Matthew W. Harding (3 shared papers)Lori E. Kronish (6 shared papers)Mohammad Jahanzeb (5 shared papers)Joanne E. Mortimer (3 shared papers)Mark Allen O’Rourke (2 shared papers)Furhan Yunus (1 shared paper)James L. Speyer (1 shared paper)
- Journals
- Journal of Clinical Oncology (4 papers)Lung Cancer (2 papers)Annals of Oncology (2 papers)European Journal of Cancer (2 papers)Clinical Cancer Research (1 paper)
- Partner nations
- United StatesCanada
In The Last Decade
Alan J. Koletsky
20 papers receiving 913 citations
Alan J. Koletsky's Hit Papers
Peers
Comparison fields: 5 of 58
- Pulmonary and Respiratory Medicine 460
- Oncology 237
- Virology 13
- Transplantation 9
- Molecular Biology 154
Countries citing papers authored by Alan J. Koletsky
This map shows the geographic impact of Alan J. Koletsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan J. Koletsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan J. Koletsky more than expected).
Fields of papers citing papers by Alan J. Koletsky
This network shows the impact of papers produced by Alan J. Koletsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan J. Koletsky. The network helps show where Alan J. Koletsky may publish in the future.
Co-authors
The 25 scholars most cited alongside Alan J. Koletsky, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2022 | 212 |
| 2 | 1986 | 201 | |
| 3 | 1996 | 107 | |
| 4 | 2002 | 107 | |
| 5 | Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study Hit paper breakdown → | 2024 | 99 |
| 6 | 2015 | 70 | |
| 7 | 1986 | 49 | |
| 8 | 1999 | 48 | |
| 9 | 1989 | 26 | |
| 10 | 2003 | 17 | |
| 11 | Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: a phase II study. | 2004 | 9 |
| 12 | 2001 | 6 | |
| 13 | 2014 | 6 | |
| 14 | Modulation of doxorubicin dox resistance by cyclosporin a csa and a non immunosuppressive homolog | 1987 | 5 |
| 15 | 2014 | 4 | |
| 16 | RATIONALE FOR TRIALS STUDYING PEGYLATED LIPOSOMAL DOXORUBICIN IN METASTATIC BREAST CANCER | 1997 | 3 |
| 17 | 2000 | 3 | |
| 18 | 1995 | 1 | |
| 19 | Weekly herceptin with navelbine in chemonaïve patients with HER2 positive metastatic breast cancer: A phase II multicenter trial | 2001 | 1 |
| 20 | Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer | 2016 | 1 |
About Alan J. Koletsky
Alan J. Koletsky is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Epidemiology, Biomaterials and Cancer Research, having authored 21 papers that have together received 975 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (6 papers), Lung Cancer Treatments and Mutations (3 papers), HER2/EGFR in Cancer Research (3 papers), Lung Cancer Diagnosis and Treatment (2 papers), Multiple and Secondary Primary Cancers (2 papers), Drug Transport and Resistance Mechanisms (2 papers), Renal cell carcinoma treatment (2 papers) and Signaling Pathways in Disease (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (460 citations), Oncology (237 citations), Virology (13 citations), Transplantation (9 citations) and Molecular Biology (154 citations). Alan J. Koletsky has collaborated with scholars based in United States and Canada. Frequent co-authors include Robert E. Handschumacher, Matthew W. Harding, Lori E. Kronish, Mohammad Jahanzeb, Joanne E. Mortimer, Mark Allen O’Rourke, Furhan Yunus, James L. Speyer, Paula Klein and David H. Irwin. Their work appears in journals such as Journal of Clinical Oncology, Lung Cancer, Annals of Oncology, European Journal of Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.